Blocking the CD80 and CD86 costimulation molecules: lessons to be learned from animal models

Area of Science:

• Immunology
• Transplantation Science
• Drug Development

Background:

• The ultimate goal in transplantation is achieving allograft tolerance, eliminating the need for immunosuppression.
• Immunoregulatory antibodies and costimulation blockade are being explored as strategies to induce donor-specific nonresponsiveness.
• Previous studies in rodents and in vitro models suggested T-cell anergy via costimulation blockade.

Purpose of the Study:

• To evaluate the efficacy of costimulation blockade in inducing tolerance in organ transplantation.
• To assess the potential of blocking the B7 costimulation pathway in nonhuman primates for graft acceptance.
• To investigate new approaches for achieving drug-free graft acceptance in transplantation.

Main Methods:

• Utilizing costimulation blockade strategies in nonhuman primate models.
• Administering B7 costimulation blockade alone or in combination with anti-CD40 or cyclosporine.
• Monitoring graft survival and donor-specific antibody formation during and after treatment.

Main Results:

• Nonhuman primate studies blocking the B7 costimulation pathway did not achieve permanent, drug-free graft acceptance.
• During treatment with B7 costimulation blockade (alone or with anti-CD40/cyclosporine), no graft loss occurred.
• Donor-specific antibody formation was successfully prevented during the treatment period.

Conclusions:

• Costimulation blockade is a promising approach for preventing acute graft rejection and antibody formation in transplantation.
• While not achieving permanent tolerance alone, costimulation blockade warrants further investigation for novel therapeutic strategies.
• New research directions are needed to achieve sustained, drug-free graft acceptance in organ transplantation.